Selected Publications

Stephenson AJ, Smith A, Kattan MW, Satagopan J, Reuter VE, Scardino PT, Gerald WL. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 2005 Jul 15; 104(2)290-8.

Karakiewicz PI, Benayoun S, Kattan MW, Perrotte P, Valiquette L, Scardino PT, Cagiannos I, Heinzer H, Tanguay S, Aprikian AG, Huland H, Graefen M. Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen. J Urol. 2005 Jun;173(6):1930-4.

Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW. Assessment of the enhancement in predictive accuaracy provided by systemic biopsy in predicting outcome for clinicaly localized prostate cancer. J Urol. 2004 Jan;171(1):200-3.

Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, Shariat S, Muramoto M, Reuter VE, Wheeler TM, Scardino PT. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol. 2004 May;171(5):1844-9;discussion 1849.

Diblasio CJ, Kattan MW. Use of nomograms to predict the risk of disease recurrence after difinitive local therapy for prostate cancer. Urology. 2003 Dec 29;62 Suppl 1:9-18.

Blute ML, Bergstralh EJ, Partin AW, Walsh PC, Kattan MW, Scardino PT, Montie JE, Pearson JD, Slezak JM, Zincke H. Validation of Partin tables for predicting pathologic stage of clinically localized prostate cancer. J Urol. 2000;164:1591-1595.

Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352-3359.

Eastham JA, May R, Robertson JL, Sartor O, Kattan MW. Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL. Urology. 1999;54:709-713.

Kattan MW, Wheeler TM, Scardino PT. A postoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499-507.

Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766-771.

Kattan MW, Stapleton AM, Wheeler TM, Scardino PT. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997;79:528-537.

Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.

Kattan MW, Ishida H, Scardino PT, Beck JR. Applying a neural network to prostate cancer survival data. In: Lavra N, Karavnou E, Zupan B, eds. Intelligent Data Analysis in Medicine and Pharmacology. Boston: Kluwer Academic; 1997: 295-306.

D'Amico AV, Moul J, Kattan MW. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers, and neural networks. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams & Wilkins; 2000:680-700.

Slawin KM, Kattan MW, Scher HI, Scardino PT. Prostate-specific antigen in screening, prognosis of the primary tumor and monitoring of recurrent disease. In: Perry MC, ed. ASCO 2000 Spring Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2000:596-608.

Zupan B, Demsar J, Kattan MW, Beck JR, Bratko I. Machine learning for survival analysis: A case study on recurrence of prostate cancer. In: Horn W, Shahar Y, Lindberg G, Andreassen S, Wyatt J, eds. Artificial Intelligence in Medicine (Lecture Notes in AI 1620). Berlin: Springer-Verlag; 2000:346-355.

Return to Prediction Tools Main Page

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org